Celldex Using MDxHealth's MGMT Test for Vaccine Trial | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth said today that Celldex Therapeutics will use its epigenetic MGMT test during recruitment of patients for a Phase III clinical study of Celldex's immunotherapeutic vaccine, rindopepimut, in newly diagnosed glioblastoma multiforme.

The study is expected to recruit 374 patients with newly diagnosed EGFRvIII-expressing GBM, an aggressive form of brain cancer, following gross total resection at more than 150 global clinical sites.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.